Burning Rock Biotech (NASDAQ:BNR) Stock Price Down 4.1%

Burning Rock Biotech Limited (NASDAQ:BNR) shares fell 4.1% during trading on Wednesday . The company traded as low as $6.19 and last traded at $6.24. 8,197 shares traded hands during trading, an increase of 34% from the average session volume of 6,099 shares. The stock had previously closed at $6.51.

Burning Rock Biotech Price Performance

The firm has a fifty day moving average price of $6.64 and a two-hundred day moving average price of $7.40. The stock has a market capitalization of $63.94 million, a PE ratio of -0.97 and a beta of 0.17.

Burning Rock Biotech (NASDAQ:BNR) last released its earnings results on Wednesday, May 29th. The company reported ($0.16) earnings per share for the quarter. The business had revenue of $17.40 million for the quarter. Burning Rock Biotech had a negative return on equity of 71.22% and a negative net margin of 113.39%.

Institutional Trading of Burning Rock Biotech

A hedge fund recently raised its stake in Burning Rock Biotech stock. Kynam Capital Management LP lifted its holdings in Burning Rock Biotech Limited (NASDAQ:BNR) by 2.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 8,694,426 shares of the company’s stock after purchasing an additional 194,426 shares during the period. Burning Rock Biotech comprises 0.9% of Kynam Capital Management LP’s holdings, making the stock its 20th biggest position. Kynam Capital Management LP owned 8.47% of Burning Rock Biotech worth $8,086,000 as of its most recent SEC filing. 30.03% of the stock is currently owned by institutional investors and hedge funds.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.